The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.
The St. Louis-based firm will use the funds to develop its colorectal cancer screening test, which measures eukaryotic RNA isolated from epithelial cells in stool.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The firm will use the funding to advance its enzymatic DNA synthesis technology, which has applications in life sciences, information storage, synthetic biology, and electronics.
The Seattle startup is looking to partner with pharmaceutical companies and offer its yeast fusion sequencing technology as a contracted research service.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.
